References
- Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli TH, Lakasas G. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004;15:475–478.
- Barradas MA, O’Donoghue S, Mikhailidis DP. Measurement of platelet volume using a channelyzer: Assessment of the effect of agonists and antagonists. In vivo 1992;6:629–634.
- Barradas MA, Jagroop IA, O’Donoghue S, Jeremy JY, Mikhailidis DP. Effect of milrinone on human platelet shape change, aggregation and thromboxane A2 synthesis: An in vitro study. Thromb Res 1993;71:227–236.
- Jagroop IA, Barradas MA, Mikhailidis DP. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996;41:163–165.
- Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP. Shape change on human platelets-measurements with a channelyzer and visualisation by electron microscopy. Platelets 2000; 11:28–32.
- Jagroop IA, Mikhailidis DP. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 2000;11:161–165.
- Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: Effect of losartan. J Hum Hypertens 2000;14:581–585.
- Jagroop IA, Mikhailidis DP. Doxazosin a selective a1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens 2001;15:203–207.
- Jagroop IA, Mikhailidis DP. Effect of endotheiln-1 on human platelet shape change: Reversal of activation by naftidrofuryl. Platelets 2000;11:277–282.
- Mikhailidis DP, Barradas MA, O’Donoghue S, Dandona P. Evidence for in vivo platelet activation following the injection of conventional unfractionated heparin. Platelets 1990;1:189–192.
- Nystrom ML, Barradas MA, Jeremy JY, Mikhailidis DP. Platelet shape change in whole blood: Differential effects of endotoxin. Thromb Haemost 1994;71:646–650.
- Jagroop IA, Burnstock G, Mikhailidis DP. Both the ADP receptors, P2Y1 and P2Y12, play a role in controlling shape change in human platelets. Platelets 2003;14:15–20.
- Nadar S, Blann A, Kamath S, Beevers D, Lip G. Platelet indexes in relation to target organ damage in high-risk hypertensive patients. JACC 2004;44:415–422.
- Sharpe PC, Trinick T. Mean platelet volume in diabetes mellitus. Q J Med 1993;86;739-742.
- Tschope D, Langer E, Schauseil S, Rosen P, Kaufmann L, Gries FA. Increased platelet volume - Sign of impaired thrombopoiesis in diabetes mellitus. Klin Wochenschr 1989;15:253–259.
- Brown AS, Hong Y, de Belder A, Beacon H, Beeso J, Sherwood R, Edmonds M, Martin JF, Erusalimsky JD. Megakaryocyte ploidy and platelet changes in human diabetic atherosclerosis. Atheroscler Thromb Vasc Biol 1997;17:802–807.
- Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R. Mean Platelet Volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002;117:399–404.
- Hekimsoy Z, Payzin B, Ornek T, Kandogan. Mean platelet volume in type 2 diabetic patients. J Diab Complications 2004;18:173–176.
- Bath PM, Butterworth RJ. Platelet size: Measurement physiology and vascular disease. Blood Coag Fibrinolys 1996;7:157–161.
- Barradas MA, Stansby G, Hamilton G, Mikhailidis DP. Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol 1994;13:202–207.
- Barradas MA, Stansby G, Hamilton G, Mikhailidis DP. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral disease. In vivo 1993;7:543–548.
- Inui Y, Suehiro T, Kumon Y, Hashimoto K. Platelet volume and urinary prostanoid metabolites in non- insulin-dependent-diabetes-mellitus. J Atheroscler Thromb 1994;1:108–112.